TILRAY brands report a strong first quarter of financial results, emphasizing continuous growth with a record Q1 $ 210 million and net income
Operating efficiency and focus on the profitability of $ 1.5 million net income, adjusted EBITDA increased from 9% to $ 10 million, and $ 34 million annually improved.
Canadian adult Canadian Cannabis gross revenues increased by 12%, maintaining a position # 1 in the expansion of income and market share. International women’s income increased by 10%
Balance reinforced to $ 265 million in cash; Net debt has been reduced to $ 4 million
Repeats EBITDA Outlook adjusted for $ 2026 – $ 72 million
New York and London and London, Ontario, October 09, 2025 (Globe Newswire) – TILRAY Brands, Inc. (“Tilray”, “Our”, “We” or “Company”) (NASDAQ. TLRY; TSX.
His Evin D. Simon, President and Chief Executive Officer, as we enter 2026 financial, the results of the first quarter of “Tilra” outlines our shareholders of our strategic vision and disciplinary balance. Our global platform positions TILRAY brands will not only participate, but also to guide, global hemp, beverages and health effects. “
Mr. Simon continued. It is available to expand access, innovation and supports the world’s responsible regulatory progress. These achievements and nominated tendencies strengthen my unbreakable belief in the trajectory of the trail of Tilra and our ability to give our investors long-term value.
Financial needs: All comparisons made in the previous year
Net incomes increased by 5% in the first quarter to $ 209.5 million compared to 200.0 million.
Gross profit in the first quarter amounted to $ 57.5 million compared to $ 59.7 million.
Gross margin in the first quarter was 27% compared to 30%.
Cannabis Net revenues increased by 5% in the first quarter to $ 64.5 million, which is $ 61.2 million.
The gross gain of greens in the first quarter amounted to $ 23.3 million compared to $ 24.2 million.
The gross Cannabis margin in the first quarter was 36% compared to 40%.
The net income of the beverages in the first quarter amounted to $ 55.7 million compared to $ 56.0 million.
The gross profit in the first quarter amounted to $ 21.3 million compared to $ 22.9 million.
The gross margin in the first quarter was 38% compared to 41%.
Net health revenues increased to $ 15.2 million in the first quarter, compared to $ 14.8 million.
The gross health margin in the first quarter was 32% and unchanged.
The distribution net income in the first quarter amounted to $ 74.0 million compared to $ 68.1 million.
The distribution of gross margin in the first quarter was 11% compared to 12%.
Net income was $ 1.5 million in the first quarter, compared to the net loss of the dollar (34.7) million.
The regulated net income increased by $ 10.0 million in the first quarter to $ 3.9 million compared to $ (6.1) million.
Settled EBITDA increased by 9% in the first quarter to $ 10.2 million compared to $ 9.3 million.
Cash flow. The cash used in the operation has significantly improved by $ 34.0 million (1.3) million (35.3) million.
Balance update. In the first quarter, TILRAY reduced its outstanding debt for $ 7.7 million, further strengthening the balance. As a result, the net debt ratio related to the twelve months adjusted EBITDA was reduced to 0.07X. Our $ 264.8 million in cash is providing great tiltric flexibility for strategic opportunities.
Live audio web web
These results in the morning 8: 30 o’clock at 8 o’clock. On 30, web brands will be conducted to discuss these results. Investors can connect to the Department of Measures and Presentations of LIVEST Investors. Reproduction will be presented on the company’s website.
About TILRAY brands
TILRAY Brands, Inc. (Nasdaq: TLRY; TSX; TSX
For more information on how we raise life through communication moments, visit Tilray.com and follow all the social platforms of @ TILRAY.
NCV NewsWire aims to treat high-quality content and information about cannabis companies by New Cannabis Ventures to help our readers make noise and remain the most important cannabical business news. NCV Newswire is hand treated by hand and is not automated. Have secret news tip. Contact:A number
You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.
friends,
About three months ago, this newsletter talked about cannabis stock traders care a lot about MSOs again, but that they weren’t paying attention to an older MSO that was in the process of getting much bigger, Vireo Growth. As I mentioned at the time, despite its very large size, Vireo Growth failed to join the Global Cannabis Stock Index due to its low trading volume. Yesterday I went through the quarterly rebalancing process for the upcoming new quarter, which starts seven days from the close of trade, and Vireo still doesn’t qualify. The price then topped the low of $0.50 at $0.5682, but the stock has traded an average of just 221,000 shares per day over the past month. The dollar volume is about $100,000, which is well below the required minimum.
I shared that there weren’t many analysts following Vireo three months ago, and that remains the case. The Vireo Growth website has no analysts listed on it analyst coverage pageSeeking Alpha shares analyst estimates, noting that there is one analyst. I use a system, Koyfin, and it has the same ratings. As I mentioned, Zuanic & Associates does cover the stock, but I don’t think its ratings are included in the consensus. It expects Vireo’s revenue to grow to $436 million in 2026 from $259.9 million in 2025, according to a report in mid-November.
Since then, the company has announced two pending transactions and purchased a large number of senior convertible debt Schwazze at a discounted price. This month, the company said it was buying some assets PharmaCann: in Colorado and that it goes to Eaze to enter California and Florida. Vireo is very active in consolidating the cannabis industry. A year ago, the company was located in Minnesota, which was used for adults, and Maryland, and it had a failed business in New York. Its Q3 report reflected acquisitions in Missouri, Nevada and Utah. Total revenue of $91.7 million includes $12.0 million in Minnesota, $10.4 million in Maryland, $6.1 million in New York (mostly wholesale) and $63.2 million from new states. The Vireo is up NCV revenue ratingReaching #7 among MSOs with positive operating income in the third quarter;
While Vireo Growth is No. 7 among MSOs by revenue, it is No. 11 in the AdvisorShares Pure US Cannabis ETF ( MSOS ), which has a holding of just 0.6% of the fund. The 9.51 million shares controlled by MSOS are down from last week as the ETF faced some redemptions, but it’s still well up from 6.9 million shares at midyear and 6.7 million at the end of 2024. At the end of June, the share was 1.0% of the ETF, so it’s down. The top three positions represent an average of 22.4% MSOS each, which is 36X greater than the VREOF position. This is not at all consistent with its market share or market cap.
Vireo Growth made a very large capital raise in late 2024, selling $81 million a share at $0.625, and it recently traded below that level and closed there today. It issued a lot of shares to cover its acquisitions. In fact, the company reports more than 1 billion shares outstanding. The stock ended 2024 at $0.56, so it’s up 11.6% this year. This compares with the Global Hemp Stock Index at 6.92, up 0.6%, and MSOS returning 24.7%.
I think cannabis investors should keep a close eye on Vireo stock for a sign of the health of the overall cannabis sector. At 420 Investor, I include 19 hemp stocks in my Focus List, and this group does not include Vireo Growth. I keep an eye on it though because it is part of a group of 7 stocks that I have on my stock watchlist to potentially add to the Focus List. While it is not in the index, the other six are or will be in a week.
I wish the best for Vireo Growth and a Merry Christmas to all New Cannabis Ventures readers.
Sincerely,
Alan:
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we published last week.
Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.
Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
Statistics Canada released October retail sales for the country, with Cannabis sales decline from September levels, down 4.7% to C$451.7 million. This sequential decline was further reduced on a daily basis due to the higher number of days compared to the previous month. September, originally reported at C$475.0 million, was revised slightly lower to C$473.9 million. October sales fell 0.9% year-over-year, down from 8.3% in May, 7.5% in June and 6.2% in September. This was also below the 20.3% growth rate in August 2023 and equal to the previous lowest annual growth rate since the start of legalization, which was -0.9% in September 2024, and it was significantly down from the 9.1% growth in December. August’s record level was only 1.8% higher than last year’s index. Total sales are expected to grow 4.5% to C$5.39 billion in 2024 and 4.3% year-to-date in 2025.
An increase in the number of shops, as well as a fall in the prices of flowers that attract consumers from the illegal market, have boosted sales. In Ontario, the most populous province, sales rose 0.1% from September and 3% from a year ago. Alberta grew 5.5% from September and 4% from a year ago. British Columbia was down 55.0% from September, as it was down 54% from a year ago, while Quebec was up 8.8% from September and 31% from a year ago.
November sales data will be released on January 23.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.
friends,
The big news this week was an extension of the huge news from August, when President Trump appears to be now preparing to issue an executive order to push cannabis from Schedule I to Schedule III. Unsurprisingly, hemp stocks have rallied, with the NCV Global Cannabis Stock Index now at 8.23, up 35.4% in December and now up 19.6% year-to-date. MSOs to benefit from 280E tax If this continues, MSOS will rise even further to 6.69, up 92.2% in December and 75.6% year-to-date. The ETF, which closed at $6.87 on Election Day 2024, fell to $2.02 in March.
In August, when the news broke, I issued a newsletter pitching to investors consider hemp REITs. After initially moving higher, they have since fallen behind;
Since 8/13, MSOS has advanced 28.4% and the Global Cannabis Stock Index is up 15.9%. Only one of the four hemp REITs rallied, Innovative Industrial Properties, and it was up just 6.9%. A very weak one is Advanced Flower Group, which is in the process of becoming a business development company
I continue to believe that eliminating 280E taxes will be good for hemp REITs, which include two equity REITs and two mortgage REITs. I have two of them, IIPR and REFI, in my Focus List at 420 Investor and my model portfolio holds both right now. I’m overweight the utilities index and underweight all other subsectors, including MSOs and Canadian LPs;
The two REITs I include in my Focus List make up 27.8% of the model portfolio and increase my ancillary exposure. All four REITs are in the Global Hemp Stock Index and make up 13.6% of the index, so I am currently very overweight. IIPR, which trades on the NYSE, trades at 0.7X tangible book value. REFI, which trades on the NASDAQ, trades at 0.9X. Both stocks pay very high dividends that may be at risk. So far in 2025, both stocks are down more than 12%, and two other hemp REITs are down more. Even if dividends are included, all are down year-over-year;
The two REITs I follow closely serve MSOs: IIPR owns and leases properties, and REFI owns mortgages that MSOs take out against their properties. The poor financial health of their clients weighed on both stocks. If 280E goes away, the client will be healthier. Certainly there will be challenges if 280E remains, but it could be much worse for MSOs saddled with debt and unpaid taxes. The reprogramming will not automatically result in NASDAQ admitting MSOs for trading, nor will it necessarily result in SECURITY banking, an action that could increase competition for REITs. Hemp REITs, which are still down year-over-year and down for much longer periods, look attractive to me for hemp investors here.
This fight to stop 280E taxation was bitter. Let’s hope it ends.
Sincerely,
Alan:
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we published last week.
Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.
Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
